PARTNERED

• Antibodies currently approved for cancer therapy lack the ability to directly penetrate into cells.
• 3e10 is a cell-penetrating anti-DNA antibody with clinical data for another indication that has been identified as a therapeutic for the treatment of cancer.
• Active as a single agent against tumors with deficits in DNA repair, e.g. BRCA mutations
• Significantly enhances sensitivity to DNA-damaging therapies (e.g. radiation, doxorubicin).
• Inventors: James Hansen, Peter Glazer
• IP status: PCT/US2015/047174 filed

As shown in the graph, a mouse xenograft model using U87 human glioma cells demonstrate that the cell-penetrating antibody synergizes with doxorubicin in vivo.